Hitoshi Fujiwara

Hitoshi Fujiwara

Auto-generated profile, based on publicly available information

Hitoshi Fujiwara

Kyoto Prefectural University of Medicine

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
HFHitoshi Fujiwara
Hitoshi Fujiwara
ASAtsushi Shiozaki
Atsushi Shiozaki
HKHirotaka Konishi
Hirotaka Konishi
TKToshiyuki Kosuga
Toshiyuki Kosuga
SKShuhei Komatsu
Shuhei Komatsu
EOEigo Otsuji
Eigo Otsuji

14 December 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
GSGen Suzuki
Gen Suzuki
Hideya YamazakiHideya Yamazaki
Hideya Yamazaki
NANorihiro Aibe
Norihiro Aibe
KMKoji Masui
Koji Masui
NSNaomi Sasaki
Naomi Sasaki
KYKei Yamada
Kei Yamada
The standard treatment for superficial esophageal cancer (SEC) involving muscularis mucosal (T1a-MM) or submucosal (T1b) invasion has been the surgical resection of the esophagus. However, esophagectomy with extended lymph node dissection is highly invasive. Recent reports have shown that endoscopic submucosal dissection (ESD) followed by chemoradiotherapy (CRT) has promising results and might become a new therapeutic approach. This retrospective study aimed to elucidate the efficacy and safety of this new treatment. Patients with clinical stage T1b tumor without apparent metastasis treated with ESD followed by CRT from 2014 to 2017 (the CRT group) were included. The outcomes on disease-free survival (DFS) of this group were compared with those of consecutive patients in a historical control group who underwent ESD followed by esophagectomy (the esophagectomy group) between 2008 and 2015. Of 32 patients analyzed, 16 were in the CRT group and 16 with similar stage cancer were in the esophagectomy group. Radiotherapy was completed in all patients, and the incidence of grade ≥ 3 nonhematologic adverse events was 6%. The 2-year overall survival rates were 100%, and locoregional control was achieved in all patients in the CRT group, and the 2-year DFS rates were 88 and 100% for the CRT and esophagectomy groups, respectively, without significant differences. Our data confirmed our new approach as being safe and effective for locoregional control and may provide a nonsurgical treatment option for patients with clinical stage T1b tumors.

26 July 2016 in Journal of Visualized Surgery
Verified
Journal Article
Closed access
PDF file
HFHitoshi Fujiwara
Hitoshi Fujiwara
ASAtsushi Shiozaki
Atsushi Shiozaki
HKHirotaka Konishi
Hirotaka Konishi
EOEigo Otsuji
Eigo Otsuji
Background: Mediastinoscope-assisted transhiatal esophagectomy (MATHE) is a minimally invasive option for thoracic esophageal cancer with the potential benefit of decreasing pulmonary complications by avoiding one-lung ventilation or a transthoracic procedure. However, the conventional MATHE procedure is less radical than transthoracic esophagectomy due to operative view limitations and insufficient mediastinal lymphadenectomy. In upper mediastinal dissection, the conventional MATHE procedure only provides esophageal mobilization with or without lymph node sampling. We developed a novel MATHE procedure with en bloc mediastinal lymphadenectomy by introducing a single-port laparoscopic technique. Methods: The patient was placed in a supine position with bilateral lung ventilation. The upper mediastinal dissection, using a left cervical approach, was performed with a single-port mediastinoscopic technique. A laparoscope was used as a ‘mediastinoscope’. The lymph nodes along the right recurrent laryngeal nerve (RLN) were dissected under direct vision using a right cervical approach. Bilateral cervical approaches were followed by hand-assisted laparoscopic transhiatal esophagectomy. Results: A single-port technique provides a favorable expansion of the mediastinal space by carbon dioxide insufflation, and improves the visibility and handling in the deep mediastinum around the aortic arch, allowing for en bloc lymphadenectomy in the upper mediastinum including the subaortic arch lymph nodes. In addition, a hand-assisted laparoscopic transhiatal procedure allows for en bloc lymphadenectomy in the middle and lower mediastinum including the subcarinal and bilateral main bronchial lymph nodes. Cervical and transhiatal procedures were performed safely and carefully under video-assisted magnified vision according to the standardized procedure with an appropriate operative field expansion using retractors. Conclusions: Single-port MATHE is feasible as a novel minimally invasive surgery for esophageal squamous cell carcinoma (ESCC) or thoracic esophageal cancer.

16 April 2002 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
TKT Kubota
T Kubota
HFH Fujiwara
H Fujiwara
YUY Ueda
Y Ueda
TIT Itoh
T Itoh
TYT Yamashita
T Yamashita
HYH Yamagishi
H Yamagishi
Cimetidine, a H2 receptor antagonist, has been reported to improve survival in gastrointestinal cancer patients. These effects have largely been attributed to the enhancing effects of cimetidine on the host's antitumour cell-mediated immune response, such as inhibition of suppressor T lymphocyte activity, stimulation of natural killer cell activity and increase of interleukin-2 production from helper T lymphocytes. We conducted an in vitro study on the effects of cimetidine on differentiation and antigen presenting capacity of monocyte-derived dendritic cells from advanced colorectal cancer patients and normal controls. As a result, an investigation of expression of surface molecules associated with dendritic cells by flow cytometric analyses showed that cimetidine had no enhancing effect on differentiation of dendritic cells from cancer patients and normal controls. An investigation of [3H]thymidine incorporation by allogeneic mixed lymphocyte reactions revealed that cimetidine increased the antigen presenting capacity of dendritic cells from both materials. Moreover, a higher antigen presenting capacity was observed in advanced cancer patients compared to normal controls. These effects might be mediated via specific action of cimetidine and not via H2 receptors because famotidine did not show similar effects. Our results suggest that cimetidine may enhance the host's antitumour cell-mediated immunity by improving the suppressed dendritic cells function of advanced cancer patients.

14 June 2022 in Oncology Letters
Verified
Journal Article
Open access
PDF file
HIHiroyuki Inoue
Hiroyuki Inoue
ASAtsushi Shiozaki
Atsushi Shiozaki
HFHitoshi Fujiwara
Hitoshi Fujiwara
HKHirotaka Konishi
Hirotaka Konishi
JKJun Kiuchi
Jun Kiuchi
EOEigo Otsuji
Eigo Otsuji
Predicting the prognosis and adverse events (AEs) of nivolumab therapy for recurrent esophageal cancer is very important. The present study investigated whether a simple blood biochemical examination could be used to predict prognosis and AEs following nivolumab treatment for relapse of esophageal cancer. A total of 41 patients who received nivolumab treatment for recurrent esophageal cancer after esophagectomy were analyzed. The absolute lymphocyte count (ALC), neutrophil‑lymphocyte ratio (NLR), platelet‑lymphocyte ratio (PLR), monocyte‑lymphocyte ratio (MLR) and C‑reactive protein‑albumin ratio (CAR) were assessed at the time of nivolumab induction as indices that can be calculated by blood biochemical examinations alone. Median values were 1,015 for ALC, 3.401 for NLR, 242.6 for PLR, 0.458 for MLR and 0.119 for CAR, and patients were divided into two groups according to values. A high ALC, low NLR, low PLR, low MLR and low CAR were associated with a better response to nivolumab. In addition, patients with the aforementioned indices, with the exception of low PLR, or better response were more likely to develop AEs in univariate analysis. In multivariate analysis, a high ALC [odds ratio (OR): 4.857, P=0.043] and low CAR (OR: 9.099, P=0.004) were identified as independent risk factors for AEs. Survival analysis revealed that overall survival and progression‑free survival (PFS) rates after nivolumab treatment differed significantly between the high and low groups of ALC, NLR, PLR, MLR and CAR. The multivariate analysis identified a low ALC [hazard ratio (HR): 3.710, P=0.003] and high CAR (HR: 2.953, P=0.007) as independent poor prognostic factors of PFS. In conclusion, ALC and CAR have potential as biomarkers for outcomes of recurrent esophageal cancer following nivolumab treatment.

7 September 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
KNKenji Nanishi
Kenji Nanishi
HKhirotaka konishi
hirotaka konishi
KSKatsutoshi Shoda
Katsutoshi Shoda
TATomohiro Arita
Tomohiro Arita
TKToshiyuki Kosuga
Toshiyuki Kosuga
EOEigo Otsuji
Eigo Otsuji
Circular RNA is a novel endogenous non‐coding RNA that can serve as a biomarker because of its stable loop structure. We investigated and examined the utility of plasma circERBB2 as a prognostic biomarker in 70 patients with gastric cancer who underwent gastrectomy. We investigated by real‐time quantitative PCR the circERBB2 concentrations in the preoperative and postoperative plasma and the circERBB2 expression in the resected tumors. The relationships between circERBB2 concentration in plasma and the clinicopathological features and prognosis were analyzed. circERBB2 was detected in the preoperative plasma samples of 37 patients. The presence of circERBB2 in preoperative plasma (high group) was significantly correlated with lymph node metastasis (P = .035) and tended to be correlated with men (P = .069). Both relapse‐free and overall survival were significantly poor in the high group (P = .001 and P = .009, respectively). The Cox proportional‐hazard model revealed that the high group was an independent prognostic factor of relapse‐free survival (P = .038). Among 16 patients of the high group, 13 patients did not show circERBB2 in the postoperative plasma. The concentration of circERBB2 in plasma was significantly higher in patients with recurrent cancer than those recurrence‐free patients (P < .001). In 2 patients with recurrent cancer, plasma circERBB2 concentrations were increased, whereas, in 2 recurrence‐free patients, these concentrations hardly changed during the treatment progress. The circERBB2 concentrations in preoperative plasma samples can be considered as a noninvasive prognostic biomarker for gastric cancer. Furthermore, monitoring the postoperative plasma circERBB2 concentrations may be useful for detecting gastric cancer recurrences.